Q2 2026 Treace Medical Concepts, Inc Earnings Call Transcript
Key Points
- Revenue growth rate improved sequentially with case volume growth accelerating to high single-digits in Q2 2026.
- Adjusted EBITDA loss narrowed to $3.5 million in Q2 2026, showing improved profitability and leverage.
- Cash usage reduced by 57% year-to-date, strengthening the balance sheet.
- 40% of the Lapiplasty surgeon base has adopted at least one of the three new bunion systems, up from 35% in Q1.
- New product launches (SuperBite, HyperPlate XM, GreatRelease XM) are expanding the addressable market and driving adoption.
- Revenue declined 4% year-over-year in Q2 2026 due to lower stocking distributor sales and a mix shift to lower-priced products.
- Gross margin decreased to 78.5% from 79.7% in the prior year quarter.
- The company still reported a net loss of $15.9 million in Q2 2026.
- Full-year 2026 revenue guidance implies a decline of up to 4% compared to 2025, with continued revenue declines expected until Q4.
- The ASP mix shift from new MIS products is expected to persist through Q3 2026, pressuring revenue growth.
Ladies and gentlemen, thank you for standing by.
Welcome to Treace Medical Concepts second quarter 2026 earnings conference call.
(Operator Instructions)
Please be advised that today's conference is being recorded.
I would like now to turn the conference over to Trip Taylor, Investor Relations. Please go ahead.
Good morning, everyone, and welcome to our second quarter 2026 earnings conference call.
Participating from the company today will be John Treace, Chief Executive Officer and Mark Hair, Chief Financial Officer.
On this call, John and Mark will discuss the second quarter financial results and 2026 outlook. We'll then host a question-and-answer session following the prepared remarks. The earnings press release can be found in the Investor Relations section of our website at investors.treace.com.
This call is being recorded and will be archived in the Investors section of our website.
Before we begin, we would like to remind
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
